Maarten van der Doelen

Table of CO NTENTS

Chapter 1

9

General introduction and outline of the thesis Based on:

Patient selection for radium-223 therapy in patients with bone metastatic castration resistant prostate cancer: new recommendations and future perspectives. Clinical Genitourinary Cancer. 2019; 17: 79-87 .

PART I

EFFECT EVALUATION OF TARGETED ALPHA RADIONUCLIDE THERAPIES

Chapter 2

27

Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225 Actinium labeled prostate-specific membrane antigen targeted alpha-radiation therapy. Urologic Oncology. 2021; 39: 729 e7-e16 . Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration resistant prostate cancer. Frontiers in Oncology. 2021; 11: 667658. Health-related quality of life, psychological distress and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. Prostate Cancer and Prostatic Diseases. 2022.

Chapter 3

53

Chapter 4

87

PART II

PROGNOSTIC PARAMETERS IN PATIENTS TREATED WITH TARGETED ALPHA-RADIONUCLIDE THERAPIES

Chapter 5

133

Radium-223 therapy in patients with advanced castration-resistant prostate cancer with bone metastases. Lessons from daily practice. Clinical Nuclear Medicine. 2018; 43: 9-16.